# Spyre Therapeutics, Inc.: filings

SYRE · Nasdaq · CIK 1636282 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/syre.md) · [Financials](/companies/syre/financials.md) · [Filings](/companies/syre/filings.md) · [Insiders](/companies/syre/insiders.md)

## Reports and events: 257 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 218, 8-K 170, SC 13G/A 61, 3 41, SC 13G 34, 10-Q 32, CORRESP 29, 424B5 23, UPLOAD 22, 144 20, EFFECT 16, S-8 14, DEF 14A 12, S-1/A 11, 10-K 10, S-3 9, SCHEDULE 13G/A 7, 424B3 6, CT ORDER 6, POS AM 6, SC 13D/A 6, ARS 4, DEFA14A 4, SCHEDULE 13D/A 4, SCHEDULE 13G 4, 10-Q/A 3, CERTNAS 3, D 3, PRE 14A 3, S-1 3, 10-K/A 2, 8-K/A 2, S-3/A 2, SC 13D 2, SEC STAFF LETTER 2, 3/A 1, 424B4 1, 4/A 1, 5 1, 8-A12B 1, DRS 1, FWP 1, PRER14A 1, S-3ASR 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-09 | 21:00 ET | [SCHEDULE 13D/A](/filings/0001104659-26-115087.md) | Ownership report, active investor, amended | 0001104659-26-115087 |
| 2026-10-07 | 12:00 ET | [8-K](/filings/0001628280-26-065291.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001628280-26-065291 |
| 2026-09-08 | 12:01 ET | [8-K](/filings/0001636282-26-000113.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001636282-26-000113 |
| 2026-08-25 | 20:04 ET | [8-K](/filings/0001636282-26-000105.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001636282-26-000105 |
| 2026-08-04 | 20:05 ET | [8-K](/filings/0001636282-26-000098.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001636282-26-000098 |
| 2026-08-04 | 20:02 ET | [10-Q](/filings/0001636282-26-000096.md) | Quarterly report, period 2026-06-30 | 0001636282-26-000096 |
| 2026-06-23 | 01:45 ET | [SCHEDULE 13D/A](/filings/0001104659-26-076961.md) | Ownership report, active investor, amended | 0001104659-26-076961 |
| 2026-06-15 | 12:01 ET | [8-K](/filings/0001636282-26-000083.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001636282-26-000083 |
| 2026-06-01 | 20:01 ET | [8-K](/filings/0001636282-26-000075.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001636282-26-000075 |
| 2026-05-29 | 20:45 ET | [8-K](/filings/0001636282-26-000056.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001636282-26-000056 |
| 2026-05-05 | 12:05 ET | [8-K](/filings/0001636282-26-000051.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001636282-26-000051 |
| 2026-05-05 | 12:00 ET | [10-Q](/filings/0001636282-26-000050.md) | Quarterly report, period 2026-03-31 | 0001636282-26-000050 |
| 2026-04-20 | 22:00 ET | [SCHEDULE 13D/A](/filings/0001104659-26-045578.md) | Ownership report, active investor, amended | 0001104659-26-045578 |
| 2026-04-16 | 20:15 ET | [8-K](/filings/0001628280-26-025508.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001628280-26-025508 |
| 2026-04-13 | 20:29 ET | [8-K](/filings/0001628280-26-024906.md) | 2.02 Results of operations; 8.01 Other events | 0001628280-26-024906 |
| 2026-04-13 | 11:46 ET | [8-K](/filings/0001628280-26-024831.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-024831 |
| 2026-04-10 | 20:01 ET | [DEF 14A](/filings/0001636282-26-000039.md) | Proxy statement, period 2026-05-27 | 0001636282-26-000039 |
| 2026-02-19 | 21:05 ET | [8-K](/filings/0001636282-26-000022.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001636282-26-000022 |
| 2026-02-19 | 21:01 ET | [10-K](/filings/0001636282-26-000020.md) | Annual report, period 2025-12-31 | 0001636282-26-000020 |
| 2026-01-12 | 14:00 ET | [8-K](/filings/0001193125-26-009894.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-009894 |
| 2025-11-04 | 21:11 ET | [8-K](/filings/0001636282-25-000104.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001636282-25-000104 |
| 2025-11-04 | 21:01 ET | [10-Q](/filings/0001636282-25-000102.md) | Quarterly report, period 2025-09-30 | 0001636282-25-000102 |
| 2025-10-17 | 21:00 ET | [SCHEDULE 13D/A](/filings/0001104659-25-100449.md) | Ownership report, active investor, amended | 0001104659-25-100449 |
| 2025-10-15 | 20:02 ET | [8-K](/filings/0001193125-25-240237.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-25-240237 |
| 2025-10-14 | 10:19 ET | [8-K](/filings/0001193125-25-237904.md) | 2.02 Results of operations | 0001193125-25-237904 |
| 2025-08-05 | 20:09 ET | [8-K](/filings/0001636282-25-000091.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001636282-25-000091 |
| 2025-08-05 | 20:05 ET | [10-Q](/filings/0001636282-25-000089.md) | Quarterly report, period 2025-06-30 | 0001636282-25-000089 |
| 2025-06-17 | 11:35 ET | [8-K](/filings/0001193125-25-141756.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-141756 |
| 2025-06-02 | 20:02 ET | [8-K](/filings/0001636282-25-000063.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001636282-25-000063 |
| 2025-05-08 | 20:05 ET | [8-K](/filings/0001636282-25-000050.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001636282-25-000050 |
| 2025-05-08 | 20:01 ET | [10-Q](/filings/0001636282-25-000049.md) | Quarterly report, period 2025-03-31 | 0001636282-25-000049 |
| 2025-04-14 | 20:33 ET | [DEF 14A](/filings/0001636282-25-000038.md) | Proxy statement, period 2025-05-29 | 0001636282-25-000038 |
| 2025-03-06 | 21:15 ET | [8-K](/filings/0001193125-25-048423.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001193125-25-048423 |
| 2025-02-27 | 21:07 ET | [8-K](/filings/0001636282-25-000022.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001636282-25-000022 |
| 2025-02-27 | 21:02 ET | [10-K](/filings/0001636282-25-000020.md) | Annual report, period 2024-12-31 | 0001636282-25-000020 |
| 2025-01-13 | 13:08 ET | [8-K](/filings/0001193125-25-005015.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-005015 |
| 2024-11-19 | 22:15 ET | [8-K](/filings/0001628280-24-048527.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001628280-24-048527 |
| 2024-11-18 | 21:09 ET | [10-Q/A](/filings/0001636282-24-000113.md) | Quarterly report, amended, period 2024-09-30 | 0001636282-24-000113 |
| 2024-11-18 | 21:06 ET | [10-Q/A](/filings/0001636282-24-000111.md) | Quarterly report, amended, period 2024-06-30 | 0001636282-24-000111 |
| 2024-11-18 | 21:05 ET | [10-Q/A](/filings/0001636282-24-000109.md) | Quarterly report, amended, period 2024-03-31 | 0001636282-24-000109 |
| 2024-11-18 | 21:03 ET | [10-K/A](/filings/0001636282-24-000107.md) | Annual report, amended, period 2023-12-31 | 0001636282-24-000107 |
| 2024-11-18 | 21:01 ET | [8-K](/filings/0001636282-24-000105.md) | 4.02 Non-reliance on financial statements; 8.01 Other events | 0001636282-24-000105 |
| 2024-11-12 | 12:35 ET | [8-K](/filings/0001628280-24-046860.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-24-046860 |
| 2024-11-07 | 21:06 ET | [8-K](/filings/0001636282-24-000085.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001636282-24-000085 |
| 2024-11-07 | 21:01 ET | [10-Q](/filings/0001636282-24-000083.md) | Quarterly report, period 2024-09-30 | 0001636282-24-000083 |
| 2024-10-15 | 10:10 ET | [8-K](/filings/0001193125-24-237150.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-237150 |
| 2024-08-08 | 22:53 ET | [8-K/A](/filings/0001636282-24-000058.md) | 8.01 Other events | 0001636282-24-000058 |
| 2024-08-07 | 20:17 ET | [8-K](/filings/0001636282-24-000053.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001636282-24-000053 |
| 2024-08-07 | 20:06 ET | [10-Q](/filings/0001636282-24-000051.md) | Quarterly report, period 2024-06-30 | 0001636282-24-000051 |
| 2024-05-30 | 20:33 ET | [8-K](/filings/0001193125-24-150395.md) | 7.01 Regulation FD disclosure | 0001193125-24-150395 |

Page 1 of 6. [Older](/companies/syre/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:14 ET. No prices; not investment advice.